U.S. Markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
33.00+0.11 (+0.33%)
At close: 4:00PM EDT

33.05 0.05 (0.15%)
After hours: 7:40PM EDT

People also watch
MRKJNJJPMINTCGE
  • I care more about the stock price appreciation. When will it go up above $35 or $40. If PFE buys a company and becomes bigger, but the price drops, that is no good for me. If PFE cuts expenses and the stock price goes up, that is what I want. We have been in low $30 for months by now. Why the board made this company so slow moving?
  • I am trying very hard to b patient with this stock
  • mounting doubt from the Street regarding next week earnings. A 5 day slow drain where it leaks from the opening bell and closes at the low each day. PFE is sitting on a mountain of cash but its business model is stuck in the mud. Many of its late stage products are not big enough to move the needle. So what becomes of this behemoth ? Should it become a large dividend play spinning offs cash to shareholders or continue to try to be a growth company ? Right now its neither-- and Wall Stree is finding better things to do with its investments
  • should buy MRK now and take over the industry. Get them before Gilead does.
  • ANY position in PFE above $30 is risky.
    2018 is going to be bad for PFE and those so called "managers" :)
    Desperados........
    PFE is affected with disease. DANGEROUS sudden stroke or financial heart attack.
    Business model is questionable.
    2018 they are going to loose patents
    It's Bad ...It's V E R Y bad!
    there is no other exit strategy = They HAVE TO SPEND billions of $$$$
    To be, or not to be: that is the question!
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    Products

    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

    Market

    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • $OPGN conversation

    OpGen, Inc. $OPGN CEO Evan Jones to meet with Pfizer $PFE Board of Directors next week...
    http://sierraworldequityreview.blogspot.com/2017/07/show-me-money-opgen-inc-opgn-ceo-evan_16.html

    Show me the money! OpGen, Inc. (OPGN) CEO Evan Jones to meet with Pfizer (PFE) Board of Directors next week as another biotech acquisition looms predicts Sierra! Following approval from New York State for Acuitas® MDRO Gene Testing things could get v
    A blog about buying and selling stocks, penny stocks and online stock trading
    sierraworldequityreview.blogspot.com
  • $CALA conversation

    Calithera Biosciences $CALA CEO Molineaux met w Pfizer $PFE Board of Directors last week, leave with positive news..
    http://sierraworldequityreview.blogspot.com/2017/07/calithera-biosciences-cala-ceo-susan_23.html

    Calithera Biosciences (CALA) CEO Susan Molineaux met with Pfizer (PFE) Board of Directors last week, leave with positive news projects Sierra
    A blog about buying and selling stocks, penny stocks and online stock trading
    sierraworldequityreview.blogspot.com
  • Where is a good entry point?
  • $CALA conversation

    Calithera Biosciences $CALA CEO Molineaux met Pfizer $PFE Board of Directors last week, leave with positive news
    http://sierraworldequityreview.blogspot.com/2017/07/calithera-biosciences-cala-ceo-susan_22.html

    Calithera Biosciences (CALA) CEO Susan Molineaux met with Pfizer (PFE) Board of Directers last week, leave with positive news projects Sierra
    A blog about buying and selling stocks, penny stocks and online stock trading
    sierraworldequityreview.blogspot.com
  • $CALA conversation

    Vote is YES_Pfizer $PFE Board Of Directors has voted to proceed with buyout offers for $MDCX $CALA $OPGN $PPHM $NWBO http://sierraworldequityreview.blogspot.com/2017/07/vote-is-yespfizer-pfe-board-of.html

    Vote is YES_Pfizer (PFE) Board Of Directors has voted to proceed with buyout offers for these 5 Biotechs, already 2 offers are on the table predicts Sierra! The offers are anticipated to be being presented in the following order through the remainder
    A blog about buying and selling stocks, penny stocks and online stock trading
    sierraworldequityreview.blogspot.com
  • $OPGN conversation

    $OPGN OpGen CEO Evan Jones to meet with Pfizer $PFE BOD next week another biotech acquisition looms predicts Sierra! http://sierraworldequityreview.blogspot.com/2017/07/show-me-money-opgen-inc-opgn-ceo-evan.html

    Show me the money! OpGen, Inc. (OPGN) CEO Evan Jones to meet with Pfizer (PFE) Board of Directors next week as another biotech acquisition looms predicts Sierra! Following approval from New York State for Acuitas® MDRO Gene Testing things could get v
    A blog about buying and selling stocks, penny stocks and online stock trading
    sierraworldequityreview.blogspot.com
  • watch for M&A with Astra-Zeneca. CEO moving to TEVA, PFE eager. Recall they wanted the merger. MERRILL LYNCH thinks this happens by end of summer.
  • $CALA conversation

    $CALA Pfizer $PFE Board Of Directors has prepared buyout offers for these 5 Biotechs...
    http://sierraworldequityreview.blogspot.com/2017/07/spending-spreepfizer-pfe-board-of.html

    Spending Spree_Pfizer (PFE) Board Of Directors has prepared buyout offers for these 5 Biotechs, already 2 offers are on the table predicts Sierra! The offers are anticipated to be being presented in the following order through the remainder of 2017:1
    A blog about buying and selling stocks, penny stocks and online stock trading
    sierraworldequityreview.blogspot.com
  • $OPGN conversation

    $OPGN OpGen CEO Jones to meet with Pfizer $PFE Board of Directors next week as another biotech acquisition looms...
    http://sierraworldequityreview.blogspot.com/2017/07/show-me-money-opgen-inc-opgn-ceo-evan_15.html

    Show me the money! OpGen, Inc. (OPGN) CEO Evan Jones to meet with Pfizer (PFE) Board of Directors next week as another biotech acquisition looms predicts Sierra! Following approval from New York State for Acuitas® MDRO Gene Testing things could get v
    A blog about buying and selling stocks, penny stocks and online stock trading
    sierraworldequityreview.blogspot.com
  • Better the last smile than the first laughter. http://dataunion.tistory.com/12259

    Pfizer Inc_ NYSE $PFE Correlation Histogram
    PFE X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is -0.6 In other words, the correlation coefficient of the other st
    dataunion.tistory.com
  • auph breaking out
  • Thoughts on this stock? It just doesn't seem to want to go past the 34 range.
  • TherapeuticsMD, Inc.

    With An Uncertain Future, TherapeuticsMD Looks To New Prospects For Survival https://seekingalpha.com/article/4086591?source=ansh $TXMD, $AGN, $NVO, $PFE

    With An Uncertain Future, TherapeuticsMD Looks To New Prospects For Survival
    TX-004HR received a CRL on May 5, 2017. Outcome of a Type A meeting with FDA to discuss the future course for TX-004HR is expected soon. The company is getting
    seekingalpha.com
  • Amazed Yahoo board and others do not challenge the lack of effectiveness of PFE CEO and Board of Directors for so many years now. The biggest white elephant on earth. Nobody challenges them, nobody questions them. It is about time to bring new blood, talented people, exciting people and not have cash managers managing this company without a clear vision of the future. Everybody is waiting to see if they will buy another mammoth company or bring billionaire profits from abroad, but the name of the game is developing new and exciting drugs and commercialize them like nobody can. Time to say goodbye to half of the board and CEO... He is tired and is a finance guy, not a science or commercial guy... Bring excitement to a stock that should at least double in worth in the next 3 - 5 years.... A change in management I think would give the stock immediately a 15% appreciation....